SCHEMBL10841508

SCHEMBL10841508

CC(C)(C)NCC(O)c1ccc(O)cn1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.55
LMNA P02545 3/20 0.55
ADRB2 P07550 4/20 0.50
CASP7 P55210 2/20 0.50
KMT2A Q03164 2/20 0.50
TSHR P16473 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
ADRB1 P08588 2/20 0.48
KDM4E B2RXH2 1/20 0.44
CASP1 P29466 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.44
BLM P54132 1/20 0.44
ESR1 P03372 3/20 0.44
ESR2 Q92731 3/20 0.44
CYP2D6 P10635 2/20 0.43
NFKB1 P19838 2/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819384 1.00 HIF1A (0.55) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL31291101 1.00 HIF1A (0.55) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL22481252 0.84 HIF1A (0.51) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL22481311 0.84 HIF1A (0.51) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL20819349 0.83 HIF1A (0.50) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL10361058 0.83 LMNA (0.50) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL20819364 0.83 ADRB2 (0.52) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL17273622 0.83 HIF1A (0.50) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL20819365 0.83 ADRB2 (0.52) HIF1ALMNAADRB2CASP7KMT2A
SCHEMBL20819357 0.83 HIF1A (0.50) HIF1ALMNAADRB2CASP7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3952101-A BETA ADRENERGIC STIMULANT SMITHKLINE CORPORATION (US) 1976-04-20 US claimed
US-20240398770-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2024-12-05 US disclosed
US-12036210-B2 Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia ATROGI AB (SE) 2024-07-16 US disclosed
US-11357757-B2 Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia ATROGI AB (SE) 2022-06-14 US disclosed
US-20220133703-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-05 US disclosed
EP-3971168-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA Atrogi AB (SE) 2022-03-23 EP disclosed
EP-3681872-B1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2021-11-17 EP disclosed
EP-3681872-B1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2021-11-17 EP disclosed
US-20210030731-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2021-02-04 US disclosed
EP-3681872-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA Atrogi AB (SE) 2020-07-22 EP disclosed
WO-2019053427-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2019-03-21 WO disclosed
WO-2019053427-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA ATROGI AB (SE) 2019-03-21 WO disclosed
US-4632992-A Intermediates for preparing pirbuterol and analogs PFIZER INC. (US) 1986-12-30 US disclosed
EP-0058069-B1 PROCESS AND INTERMEDIATES FOR PREPARING PIRBUTEROL AND ANALOGS PFIZER INC. (US) 1986-08-27 EP disclosed
US-4477671-A 3-Acetoxy or benzyloxy-2-acetoxymethyl-6-[1-acetoxy-2-(N-tert-butylacetamido)ethyl]pyridine intermediates PFIZER INC. (US) 1984-10-16 US disclosed
EP-0058070-A3 PROCESS FOR PREPARING PIRBUTEROL PFIZER INC. (US) 1982-08-25 EP disclosed
EP-0058070-A2 Process for preparing pirbuterol PFIZER INC. (US) 1982-08-18 EP disclosed
EP-0058070-A2 Process for preparing pirbuterol PFIZER INC. (US) 1982-08-18 EP disclosed
EP-0058069-A2 Process and intermediates for preparing pirbuterol and analogs PFIZER INC. (US) 1982-08-18 EP disclosed
US-3952101-A BETA ADRENERGIC STIMULANT SMITHKLINE CORPORATION (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220133703-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA SLC5A2, SLC5A1, GPR119 HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885
US-11357757-B2 Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia SLC5A2, SLC5A1, GPR119 HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885
US-20240398770-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA SLC5A2, SLC5A1, GPR119 HIF1A 688/4885LMNA 2140/4885ADRB2 92/4885
US-12036210-B2 Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia SLC5A2, SLC5A1, GPR119 HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885
US-20210030731-A1 HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA SLC5A2, SLC5A1, GPR119 HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.